secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2026-07-16T21:02:04+00:00
Accession:  0001193125-26-306222
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies H1 2026 net loss $98M; BLA submission for peanut patch delayed to Q3 2026
--------------------------------------------------------------------------------

- Net loss of $98.0M for H1 2026 vs $69.0M for H1 2025; Q2 net loss $50.4M.
- Cash and equivalents $174.9M as of June 30, 2026, funding into Q3 2027.
- BLA submission for VIASKIN Peanut Patch (ages 4-7) now expected in Q3 2026, previously Q2.
- R&D expenses $64.6M in H1 2026, up from $55.2M, driven by clinical trials and BLA prep.
- SG&A expenses rose to $25.1M from $14.1M due to commercial infrastructure build.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/0001193125-26-306222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/d156695d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-306222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer